Executive Insights II: How COVID-19 is Transforming the Future of Drug Development

Exclusive to DCAT Member Companies

Date/Time: Wednesday, July 14, 2021 - 10:00 AM to 11:00 AM EDT


On-demand viewing of this program for registrants is now closed. Please contact Mikaela Venice at 1-609-208-1888 ext. 7015 for more information.

1-hr Webinar Featuring

  • Philip Dormitzer, M.D., Ph.D., Vice President and Chief Scientific Officer, Viral Vaccines, Pfizer
  • Rahul Singhvi, Sc.D., CEO and Director, National Resilience, Inc.

Program Highlights

  • The story behind Pfizer’s mRNA COVID-19 vaccine
  • The promise of mRNA technology, other innovative platforms, and new modalities
  • The future of R&D
  • Manufacturing innovation in drug development


Development of vaccines and treatments for COVID-19 has occurred at an unprecedented pace of scientific innovation. How was this done, and what does it mean for the future of drug development, manufacturing, and supply?

Learn how Pfizer brought the first mRNA vaccine for COVID-19 to fruition, making it the first mRNA vaccine authorized for emergency use by the FDA. Plus, hear from National Resilience Inc., a new manufacturing and technology company led by former executives from Takeda and Roche/Genentech, which launched in November 2020 with initial capital of $800 million and a specific focus on manufacturing innovation.

Learn from these executives on:

  • The potential of mRNA technology and other promising areas in R&D
  • New approaches in drug development: time-to-market and regulatory practices
  • Manufacturing of new modalities: the challenges and opportunities


  • Philip Dormitzer, M.D., Ph.D., Vice President and Chief Scientific Officer, Viral Vaccines, Pfizer
  • Rahul Singhvi, Sc.D., CEO and Director, National Resilience, Inc.
  • Moderator: Patricia Seymour, Managing Director, BioProcess Technology Group, BDO USA LLP

Who Should Attend

  • C-suite and senior to mid-level executives of Bio/Pharmaceutical Companies, including those involved in sourcing, procurement, supply management, and manufacturing.
  • C-suite and senior to mid-level executives of CDMOs/CMOs and other suppliers, including those in business development, sales, marketing, and operational functions in support of Bio/Pharmaceutical development and manufacturing.

Pricing and Registration

Online registration for this program is now closed. To register over the phone, please contact Mikaela Venice at 1-609-208-1888 ext. 7015.

The DCAT organization is pleased to offer timely and topical education sessions during DCAT Week. Compared to similar programs found in the industry’s marketplace, our program fees are deeply discounted for employees of DCAT Member Companies. 

Please note: DCAT Week 2021 programs are available to employees of DCAT Member Companies only. Not sure if your company is a DCAT member? Click here or call DCAT at 1-609-208-1888.

  • DCAT Member Company Price: $59.00

Can't make the live webinar? No problem! Registrants will have access to on-demand viewing of the program after the live date until July 31, 2021. Click here to learn more.